Trenschel Robert J.
Known title: DirectorCIK: 0001849917
Trenschel Robert J.'s purchase track record
Trenschel Robert J. has only 2 open-market purchases with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 9/8/2021 | PALI | $30K | -25.4% | -64.5% | -5.2% |
| 8/31/2021 | PALI | $12K | -17.1% | -66.9% | -4.8% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PALI | ▲ Buy | Option Exercise | 5,100 | $0 | 2/8/2024 | View on chart |
| PALI | ▲ Buy | Option Exercise | 5,820 | $0 | 2/8/2024 | View on chart |
| PALI | ▼ Sell | Open Market | 300 | $192 | 9/14/2023 | View on chart |
| PALI | ▲ Buy | Open Market | 2,142 | $6K | 9/10/2021 | View on chart |
| PALI | ▲ Buy | Open Market | 3,400 | $10K | 9/9/2021 | View on chart |
| PALI | ▲ Buy | Open Market | 5,000 | $14K | 9/8/2021 | View on chart |
| PALI | ▲ Buy | Open Market | 2,707 | $8K | 9/7/2021 | View on chart |
| PALI | ▲ Buy | Open Market | 1,750 | $5K | 8/31/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108
Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.
Palisade Bio Gets FDA and Health Canada Clearances for PALI-2108. Palisade Bio received FDA clearance for an IND to test PALI-2108 in Crohn’s disease, with first enrollment expected in Q1 next year. The company also secured Health Canada clearance for its Phase 2b ulcerative colitis trial. These regulatory approvals expand the drug's development across inflammatory bowel disease, while the stock remains near its 52-week low.